Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

The biosimilars market represents a transformative segment within the global pharmaceutical industry, offering highly similar ...

Key Points GAAP revenue surged to $4.0 million in Q2 2025, beating analyst expectations by 381.9%. GAAP net loss per share improved to $(0.50) in Q2 2025, slightly better than the estimated $(0.52).

The Fund returned approximately +14% during the second quarter, bringing our YTD returns to under +1%. Read more here.

Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the ...

Stem cell-derived exosomes in cosmetics are key for addressing aging and skin healing, offering targeted delivery of regenerative effects for healthier skin.

Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company advancing scalable human cell models derived from induced ...

ZUG, Switzerland and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Researchers at Kyoto University have discovered that an immune molecule found only in primates, called IGFL2, plays a key role in regulating ...

These soluble protein agonists can replicate Notch activation in suspension culture, opening the door to scalable T-cell therapies.

Tumors of the pancreas seldom cause symptoms in their early stages. This means that in many cases, they are not diagnosed until late, when the chances of successful treatment are poor. A new ...

Women and people assigned female at birth can't get prostate cancer, but they can get a similar type, called Skene's gland ...